These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 17941458

  • 1. [Apomorphine in off state--clinical experience].
    Rudzińska M, Szczudlik A.
    Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S40-8. PubMed ID: 17941458
    [Abstract] [Full Text] [Related]

  • 2. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D, Hanssens Y, Northway MG.
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [Abstract] [Full Text] [Related]

  • 3. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ, Obering C.
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [Abstract] [Full Text] [Related]

  • 4. Apomorphine hydrochloride for the treatment of Parkinson's disease.
    Unti E, Ceravolo R, Bonuccelli U.
    Expert Rev Neurother; 2015 Nov; 15(7):723-32. PubMed ID: 26037961
    [Abstract] [Full Text] [Related]

  • 5. Apomorphine in the treatment of Parkinson's disease.
    Hagell P, Odin P.
    J Neurosci Nurs; 2001 Feb; 33(1):21-34, 37-8. PubMed ID: 11233359
    [Abstract] [Full Text] [Related]

  • 6. [Apomorphine in the treatment of Parkinson's Disease].
    Dressler D.
    Nervenarzt; 2005 Jun; 76(6):681-9. PubMed ID: 15592807
    [Abstract] [Full Text] [Related]

  • 7. [Apomorphine in treatment of Parkinson's disease with fluctuations].
    Zaleska B, Domzał T.
    Neurol Neurochir Pol; 1999 Jun; 33(6):1297-303. PubMed ID: 10791032
    [Abstract] [Full Text] [Related]

  • 8. Apomorphine in patients with Parkinson's disease.
    Muguet D, Broussolle E, Chazot G.
    Biomed Pharmacother; 1995 Jun; 49(4):197-209. PubMed ID: 7669939
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Apomorphine - pharmacological properties and clinical trials in Parkinson's disease.
    Jenner P, Katzenschlager R.
    Parkinsonism Relat Disord; 2016 Dec; 33 Suppl 1():S13-S21. PubMed ID: 27979722
    [Abstract] [Full Text] [Related]

  • 11. Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response.
    Maggio R, Barbier P, Corsini GU.
    J Neural Transm Suppl; 1995 Dec; 45():133-6. PubMed ID: 8748618
    [Abstract] [Full Text] [Related]

  • 12. Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations.
    Carbone F, Djamshidian A, Seppi K, Poewe W.
    CNS Drugs; 2019 Sep; 33(9):905-918. PubMed ID: 31473980
    [Abstract] [Full Text] [Related]

  • 13. Apomorphine: an underutilized therapy for Parkinson's disease.
    Poewe W, Wenning GK.
    Mov Disord; 2000 Sep; 15(5):789-94. PubMed ID: 11009181
    [Abstract] [Full Text] [Related]

  • 14. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Blanchet PJ, Konitsiotis S, Chase TN.
    J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
    [Abstract] [Full Text] [Related]

  • 15. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
    Colzi A, Turner K, Lees AJ.
    J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
    [Abstract] [Full Text] [Related]

  • 16. Clinical insights into use of apomorphine in Parkinson's disease: tools for clinicians.
    Henriksen T.
    Neurodegener Dis Manag; 2014 May; 4(3):271-82. PubMed ID: 25095821
    [Abstract] [Full Text] [Related]

  • 17. Sublingual apomorphine: a new pharmacological approach in Parkinson's disease?
    Montastruc JL, Rascol O, Senard JM, Houin G, Rascol A.
    J Neural Transm Suppl; 1995 May; 45():157-61. PubMed ID: 8748621
    [Abstract] [Full Text] [Related]

  • 18. Update on apomorphine for the rapid treatment of hypomobility ("off") episodes in Parkinson's disease.
    Obering CD, Chen JJ, Swope DM.
    Pharmacotherapy; 2006 Jun; 26(6):840-52. PubMed ID: 16716137
    [Abstract] [Full Text] [Related]

  • 19. [Apomorphine: an alternative in the control of motor fluctuations in Parkinson's disease].
    Ferraz HB, Azevedo-Silva SM, Borges V, Rocha MS, Andrade LA.
    Arq Neuropsiquiatr; 1995 Jun; 53(2):245-51. PubMed ID: 7487531
    [Abstract] [Full Text] [Related]

  • 20. [Proposed alternative to standard apomorphine challenge test].
    Martínez-Castrillo JC, Burguera JA.
    Rev Neurol; 2012 Jun; 55 Suppl 1():S11-3. PubMed ID: 23169227
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.